PGN 650 I-124

Drug Profile

PGN 650 I-124

Alternative Names: 124I-PGN 650; PGN 650; PGN-650-124-I; PGN-650-I124

Latest Information Update: 26 May 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Affitech A/S; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center
  • Developer Peregrine Pharmaceuticals
  • Class Diagnostic agents; Imaging agents; Monoclonal antibody diagnostics
  • Mechanism of Action Radionuclide imaging enhancers; Tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase 0 Solid tumours

Most Recent Events

  • 09 Sep 2013 PGN 650 I-124 is still in phase 0 trials for Solid tumours (Diagnostic imaging) in USA
  • 02 Jul 2012 Phase-0 for Solid tumours (Diagnostic imaging) in USA (IV)
  • 05 Apr 2012 Peregrine Pharmaceuticals files an IND application for PGN 650 with the FDA in the USA for diagnostic imaging
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top